Completed PHASE1 INTERVENTIONAL 1-arm NCT02301754

INVAC-1 Anti-Cancer hTERT DNA Immunotherapy

A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer

Sponsor: Invectys

Interventions INVAC-1

Updated 8 times since 2017 Last updated: Feb 25, 2019 Started: Nov 30, 2014 Primary completion: Feb 28, 2018 Completion: Jun 1, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Solid Tumors, this trial is completed. The trial is conducted by Invectys and has accumulated 8 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Mar 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2018 — Mar 2019 [monthly]

Active Not Recruiting PHASE1

▶ Show 3 earlier versions

Mar 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Mar 2017 — Mar 2018 [monthly]

Recruiting PHASE1

Status: Active Not Recruiting → Recruiting
Jan 2017 — Mar 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Invectys
Keyrus Biopharma

Data source: Invectys

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France